defovir Dipivoxil Alone or in Combination With Lamivudine in atients With Lamivudine-Resistant Chronic Hepatitis B

ARION G. PETERS,* H. W. HANN,‡ PAUL MARTIN,§ E. JENNY HEATHCOTE, P. BUGGISCH,¶ . RUBIN,# M. BOURLIERE,** K. KOWDLEY,‡‡ C. TREPO,§§ D. F. GRAY,¶¶ M. SULLIVAN, . KLEBER, R. EBRAHIMI, S. XIONG, and CAROL L. BROSGART, OR THE GS-00-461 STUDY GROUP Division of Gastroenterology, University of California, San Francisco, San Francisco, California; ‡Jefferson Medical College, Philadelphia, ennsylvania; §Cedars-Sinai Medical Center, Los Angeles, California; Toronto Western Hospital, Toronto, Ontario, Canada; Universitaetsklinikum Eppendorf, Hamburg, Germany; #Digestive Healthcare of Georgia, Atlanta, Georgia; **Hopital Saint Joseph, Marseille, rance; ‡‡University of Washington Hepatology Center, Seattle, Washington; §§Hopital Hôtel Dieu, Lyon, France; ¶¶GlaxoSmithKline, reenford, Middlesex, England; and Gilead Sciences, Inc., Foster City, California

[1]  M. Wulfsohn,et al.  Adefovir dipivoxil therapy for lamivudine‐resistant hepatitis B in pre– and post–liver transplantation patients , 2003, Hepatology.

[2]  Ching-Lung Lai,et al.  Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  M. Wulfsohn,et al.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. , 2003, The New England journal of medicine.

[4]  M. Wulfsohn,et al.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. , 2003, The New England journal of medicine.

[5]  Chutima Pramoolsinsup.  Management of viral hepatitis B , 2002, Journal of gastroenterology and hepatology.

[6]  V. Calvez,et al.  Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study , 2001, The Lancet.

[7]  A. Lok,et al.  Management of hepatitis B: 2000--summary of a workshop. , 2001, Gastroenterology.

[8]  N. Leung,et al.  Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy , 2001, Hepatology.

[9]  H. Kumada,et al.  [Chronic hepatitis B]. , 2001, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology.

[10]  J. Hoofnagle,et al.  Long‐term therapy of chronic hepatitis B with lamivudine , 2000, Hepatology.

[11]  Y. Liaw,et al.  Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. , 2000, Gastroenterology.

[12]  E. Schiff,et al.  Adefovir dipivoxil for the treatment of lamivudine‐resistant hepatitis B mutants , 2000, Hepatology.

[13]  A. Dhillon,et al.  Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial , 2000, Gut.

[14]  C. Gibbs,et al.  In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance , 2000, Hepatology.

[15]  M. Wulfsohn,et al.  Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial. , 1999, JAMA.

[16]  E. Schiff,et al.  Extended lamivudine retreatment for chronic hepatitis B: Maintenance of viral suppression after discontinuation of therapy , 1999, Hepatology.

[17]  C. Chu,et al.  Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy , 1999, Hepatology.

[18]  C. Gibbs,et al.  Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro , 1998, Hepatology.

[19]  Ding‐Shinn Chen,et al.  Hepatitis B Virus Infection , 2007 .

[20]  R. Pugh,et al.  Transection of the oesophagus for bleeding oesophageal varices , 1973, The British journal of surgery.

[21]  E. Schiff,et al.  Histological outcome during long-term lamivudine therapy. , 2003, Gastroenterology.